Charlie Silver (Mission Bio)

'We want to be every­where.' Mis­sion Bio rais­es $70M be­hind re­sis­tance-hunt­ing se­quenc­ing plat­form

Char­lie Sil­ver wants to look re­al­ly, re­al­ly close­ly at a lot of your cells. And he just got a lot of mon­ey to do so.

Sil­ver’s start­up, Mis­sion Bio, raised $70 mil­lion in a Se­ries C round Thurs­day led by No­vo Hold­ings. The mon­ey, which brings Mis­sion Bio to $120 mil­lion raised since its 2012 found­ing, will be used to ad­vance the sin­gle-cell se­quenc­ing plat­form they built to de­tect ear­ly re­sponse or re­sis­tance to new can­cer ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.